Matrix metalloproteinase inhibition attenuates left ventricular remodeling and dysfunction in a rat model of progressive heart failure

Circulation

Volumn 103, Issue 18, 2001, Pages 2303-2309

  Peterson, J Thomas ^a   Hallak, Hussein ^a   Johnson, Linda ^a   Li, Hua ^a   O'Brien, Patrick M ^a   Sliskovic, Drago R ^a   Bocan, Thomas M A ^a   Coker, Mytsi L ^b   Etoh, Takuma ^b   Spinale, Francis G ^b  

^a PFIZER INC   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Hypertension; Hypertrophy; Remodeling; Systole; Ventricles

Indexed keywords

MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; PD 166793; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG BLOOD LEVEL; ENZYME ACTIVITY; ENZYME INHIBITION; HEART FAILURE; HEART VENTRICLE FUNCTION; HEART VENTRICLE REMODELING; HEART VENTRICLE SIZE; MALE; NONHUMAN; OBESITY; PRIORITY JOURNAL; RAT; SPONTANEOUSLY HYPERTENSIVE RAT;

EID: 14344281434     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.103.18.2303     Document Type: Article

References (22)

1. Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling: concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. J Am Coll Cardiol. 2000;35:569-582.
2. Nagase H, Woessner JF Jr. Matrix metalloproteinases. J Biol Chem. 1999;274:21491-21494.
3. Gunja-Smith Z, Morales AR, Romanelli R, et al. Remodeling of human myocardial collagen in idiopathic dilated cardiomyopathy: role of metalloproteinases and pyridinoline cross-links. Am J Pathol. 1996;148: 1639-1648.
4. Li YY, Feldman AM, Sun Y, et al. Differential expression of tissue inhibitors of metalloproteinases in the failing human heart. Circulation. 1998;98:1728-1734.
5. Spinale FG, Coker ML, Bond BR, et al. Myocardial matrix degradation and metalloproteinase activation in the failing heart: a potential therapeutic target. Cardiovasc Res. 2000;46:225-238.
6. Spinale FG, Coker ML, Krombach SR, et al. Matrix metalloproteinase inhibition during the development of congestive heart failure: effects on left ventricular dimensions and function. Circ Res. 1999;85:364-376.
7. Fletcher PJ, Pfeffer JM, Pfeffer MA, et al. Left ventricular diastolic pressure-volume relations in rats with healed myocardial infarction: effects on systolic function. Circ Res. 1981;49:618-626.
8. Zile MR, Tanaka R, Lindroth JR, et al. Left ventricular volume determined echocardiographically by assuming a constant left ventricular epicardial long-axis/short-axis dimension ratio throughout the cardiac cycle. J Am Coll Cardiol. 1992;20:986-993.
9. Whittaker P, Kloner RA, Boughner DR, et al. Quantitative assessment of myocardial collagen with picrosirius red staining and circularly polarized light. Basic Res Cardiol. 1994;89:397-410.
10. Spinale FG, Coker ML, Thomas CV, et al. Time-dependent changes in matrix metalloproteinase activity and expression during the progression of congestive heart failure: relation to ventricular and myocyte function. Circ Res. 1998;82:482-495.
11. Jeffrey JJ. Interstitial collagenases. In: Parks WC, Mecham RP, eds. Matrix Metalloproteinases. San Diego, Calif: Academic Press; 1998: 15-42.
12. Ducharme A, Frantz S, Aikawa M, et al. Targeted deletion of matrix metalloproteinase-9 attenuated left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest. 2000;106:55-62.
13. McElmurray JH III, Mukherjee R, New RB, et al. Angiotensin-converting enzyme and matrix metalloproteinase inhibition with developing heart failure: comparative effects on left ventricular function and geometry. J Pharmacol Exp Ther. 1999;291:799-811.
14. Rohde LE, Ducharme A, Arroyo LH, et al. Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice. Circulation. 1999;99:3063-3070.
15. McCune SA, Park S, Radin MJ, et al, eds. SHHF/Mcc-facp Rat Model: A Genetic Model of Congestive Heart Failure. Boston, Mass: Kluwer Academic Publishers; 1995.
16. Heymans S, Luttun A, Nuyens D, et al. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat Med. 1999;5: 1135-1142.
17. Cleutjens JP, Verluyten MJ, Smiths JF, et al. Collagen remodeling after myocardial infarction in the rat heart. Am J Pathol. 1995;147:325-338.
18. Little WC, Warner JG Jr, Rankin KM, et al. Evaluation of left ventricular diastolic function from the pattern of left ventricular filling. Clin Cardiol. 1998;21:5-9.
19. Coker ML, Doscher MA, Thomas CV, et al. Matrix metalloproteinase synthesis and expression in isolated LV myocyte preparations. Am J Physiol. 1999;277:H777-H787.
20. Wallis FJ, Ramsay LE, Hettiarachchi J. Combined inhibition of neutral endopeptidase and angiotensin-converting enzyme by sampatrilat in essential hypertension. Clin Pharmacol Ther. 1998;64:439-449.
21. Roten L, Nemoto S, Simsic J, et al. Effects of gene deletion of the tissue inhibitor of the matrix metalloproteinase-type 1 (TIMP-1) on left ventricular geometry and function in mice. J Mol Cell Cardiol. 2000;32: 109-120.
22. Seccia TM, Bettini E, Vulpis V, et al. Extracellular matrix gene expression in the left ventricular tissue of spontaneously hypertensive rats. Blood Press. 1999;8:57-64.